Arrowhead Research (ARWR) Ends 1Q with $77M to Focus on HBV and AAT; Piper Jaffray Reiterates Overweight
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/23/2026
Go back to Arrowhead Research (ARWR) Ends 1Q with $77M to Focus on HBV and AAT; Piper Jaffray Reiterates Overweight
February 9, 2016 6:12 PM EST
Mast Therapeutics, Inc. (NYSE: MSTX) 37% LOWER; announced that it intends to offer shares of common stock and warrants to purchase common stock in an underwritten public offering. The offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.
SolarCity (Nasdaq: SCTY) 32.4% LOWER; reported Q4 EPS of ($2.37), $0.22 better than the analyst estimate of ($2.59). Revenue was $115 million, versus... More
February 9, 2016 4:47 PM EST
Arrowhead Research (NASDAQ: ARWR) reported Q2 EPS of ($0.32), $0.09 better than the analyst estimate of ($0.41).
For earnings history and earnings-related data on Arrowhead Research (ARWR) click here.
...
More
